All News

Real-world data show zuranolone improved postpartum depression symptoms by Day 15 with sustained benefit through Day 45.

A new executive order aims to speed up FDA access to psychedelic therapies; psychiatrist Gus Alva, MD, reviews evidence, safety risks, and more.

A secondary analysis of the FINEARTS-HF trial demonstrated consistent treatment efficacy in patients with and without a history of IHD. Details from study author Jawad Butt, MD, here.

ACP guidance recommends biennial mammography for women aged 50-74 and shared decision-making for screening in women aged 40-49.

Older adults with both anemia and elevated neurofilament light chain levels faced a more than 3.5-fold increased risk of developing dementia.

Test your knowledge of 2024 CDC STI data on high-risk populations and what it means for your screening decisions.

Explore safer IBS treatment choices for primary care: lifestyle steps and newer diarrhea/constipation meds beyond antidepressants and opioids.

Test your knowledge of 2024 syphilis trends, staging distribution, and declines in primary and secondary disease.

Phase 3 CORALreef AddOn shows oral PCSK9 inhibitor enlicitide cuts LDL 65% on statins, potentially easing primary care lipid control.

Highlights include once-weekly insulin, obesity therapies, and new options for psoriasis and rare diseases.

Try your hand at these 5 questions on the latest US CDC STI data.

A sweeping review finds women with diabetes consistently miss key preventive and reproductive services—contraception, preconception counseling, cancer and STI screening—worldwide.

Women with diabetes receive less contraception, cancer screening, and preconception care, increasing risk for preventable complications.

Experts weigh antidepressants for IBS: small but serious mortality risk, while FDA-approved IBS drugs show stronger trials and long-term safety.

Study of 669 083 patients links antidepressants and some antidiarrheals to higher mortality in IBS, raising prescribing concerns.

Explore monthly GLP‑1 dose titration, unusual strength jumps, and color‑coded pills—plus tips for switching safely from injectable regimens.

Phase 3 data show an investigational 6-valent OspA-based Lyme vaccine prevents more than 70% of cases; regulatory submissions planned.